Skip to main content

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 376-400 of 428

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Status: Active
Location: See ClinicalTrials.gov
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Status: Active
Location: See ClinicalTrials.gov
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: See ClinicalTrials.gov
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Location: See ClinicalTrials.gov
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
Status: Enrolling by Invitation
Location: Roswell Park Cancer Institute, Buffalo, New York
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Status: Enrolling by Invitation
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Autologous CAR19.20.22 Chimeric Antigen Receptor T Cells (CAR19.20.22 CART) for the Treatment of Recurrent or Refractory B-Cell Lymphomas
Status: Enrolling by Invitation
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
CD70.CAR NK Cells for the Treatment of Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Status: Approved
Location: UT MD Anderson Cancer Center, Houston, Texas
A New Molecular Biomarker Test for Adapting Neoadjuvant Treatment in Patients with HER2-Positive Early-Stage Breast Cancer, EUREKA Trial
Status: Approved
Location: 9 locations
Loncastuximab Tesirine and Rituximab for the Treatment of Patients with Post-Transplant Lymphoproliferative Disorder, PLUTO Trial
Status: Approved
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
Genetically Engineered Cells (CD45RA-Depleted CD19-CAR T Cells) after Donor Stem Cell Transplantation for the Treatment of Pediatric Patients with Relapsed/Refractory CD19-Positive Blood Cancers, HAPALL Trial
Status: Approved
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Rapcabtagene Autoleucel for the Treatment of Large B-Cell Lymphoma in Patients at High Risk for Relapse after Front-Line Therapy
Status: Approved
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
211At-OKT10-B10 and Fludarabine Alone or in Combination with Cyclophosphamide and Low-Dose TBI before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
CD19 CAR T Cells Manufactured On-Site Using the Miltenyi CliniMACS Prodigy for the Treatment of Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Status: Approved
Location: Nationwide Children's Hospital, Columbus, Ohio
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATLL)
Status: Temporarily Closed to Accrual
Location: 19 locations
Cell Therapy (CIML NK Cells) for the Treatment of Recurrent Myeloid Disease after Donor Blood Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: 3 locations
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Tazemetostat in Combination with CHOP for Previously Untreated Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 3 locations
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov